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Abstract
Arrestins are multifunctional signaling adaptors originally discovered as proteins that ‘‘arrest’’ G protein activation by G
protein-coupled receptors (GPCRs). Recently GPCR complexes with arrestins have been proposed to activate G protein-
independent signaling pathways. In particular, arrestin-dependent activation of extracellular signal-regulated kinase 1/2
(ERK1/2) has been demonstrated. Here we have performed in vitro binding assays with pure proteins to demonstrate for the
first time that ERK2 directly binds free arrestin-2 and -3, as well as receptor-associated arrestins-1, -2, and -3. In addition, we
showed that in COS-7 cells arrestin-2 and -3 association with b2-adrenergic receptor (b2AR) significantly enhanced ERK2
binding, but showed little effect on arrestin interactions with the upstream kinases c-Raf1 and MEK1. Arrestins exist in three
conformational states: free, receptor-bound, and microtubule-associated. Using conformationally biased arrestin mutants
we found that ERK2 preferentially binds two of these: the ‘‘constitutively inactive’’ arrestin-D7 mimicking microtubule-
bound state and arrestin-3A, a mimic of the receptor-bound conformation. Both rescue arrestin-mediated ERK1/2/activation
in arrestin-2/3 double knockout fibroblasts. We also found that arrestin-2-c-Raf1 interaction is enhanced by receptor
binding, whereas arrestin-3-c-Raf1 interaction is not.
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Introduction
Arrestins were first discovered as proteins that bind active
phosphorylated G-protein coupled receptors (GPCRs) and stop
(‘‘arrest’’) G protein-mediated signaling [1] due to direct
competition with G proteins for the cytoplasmic tip of the receptor
[2,3]. In the last 15 years arrestin interactions with many non-
receptor partners have been described, suggesting that arrestins
serve as versatile signaling regulators in the cell [4]. Crystal
structures of all four vertebrate arrestins [5–8] revealed a very
similar basal conformation: an elongated molecule consisting of
two cup-like domains connected by highly conserved intra-
molecular interactions. Many groups using a variety of methods
invariably mapped receptor-binding elements to the concave sides
of both arrestin domains [9–16]. Receptor binding induces a
significant conformational change [10,13,17,18], involving the
release of the arrestin C-tail and other rearrangements (reviewed
in [19–21]). Interestingly, microtubule binding, mediated by the
same concave sides of the two domains [22], induces a distinct
conformational rearrangement [22,23]. Thus, in the cell arrestins
exist in at least three distinct conformations, free, receptor-bound,
and microtubule-bound [24], and many signaling proteins
differentially bind arrestins in these states [25–27].
Specific mutants of both arrestin-2 and arrestin-3 mimicking
microtubule-associated and receptor-bound conformations were
constructed [22,23,25,28]. Note that we use systematic names of
arrestin proteins: arrestin-1 (historic names S-antigen, 48 kDa
protein, visual or rod arrestin), arrestin-2 (b-arrestin or b-
arrestin1), arrestin-3 (b-arrestin2 or hTHY-ARRX), and ar-
restin-4 (cone or X-arrestin; for unclear reasons its gene is called
‘‘arrestin 3’’ in HUGO database). Here we used wild type (WT)
non-visual arrestins and their conformationally restricted mu-
tants to determine the states that preferentially bind individual
kinases of the c-Raf1-MEK1-ERK2 (ERK, extracellular signal
regulated kinase; MEK1, dual specificity mitogen-activated
protein kinase kinase 1, encoded by the MAP2K1 gene in
humans; c-Raf1, a.k.a. c-Raf, proto-oncogene serine/threonine-
protein kinase encoded in humans by the RAF1 gene) cascade in
the presence or absence of activated b2-adrenergic receptor
(b2AR). We found that the ERK2 binding to arrestin-2 and
arrestin-3 dramatically increases when arrestins are associated
with b2AR. Arrestin-2 interaction with c-Raf1 is enhanced by
receptor binding, whereas arrestin-3-c-Raf1 interaction is not.
MEK1 interaction also does not show clear preference for
receptor-bound arrestin. Using pure proteins we present the first
evidence that the interaction of arrestins with ERK2 is direct,
and that it is differentially affected by receptor binding. These
findings improve our understanding of arrestin-mediated scaf-
folding of MAP kinase cascades and pave the way to targeted
manipulation of this branch of GPCR signaling.
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Non-visual arrestins directly bind ERK2 and facilitate its
phosphorylation by MEK1
Although ERK2 binding to arrestins was reported a decade ago
using co-immunoprecipitation [29], the proof that this interaction
is direct was never presented. However, several lines of evidence
suggest that ERK2 preferentially associates with receptor-bound
arrestins [29–31]. Therefore, first we used purified proteins to test
whether arrestins bound to model receptor light-activated
phosphorylated rhodopsin (P-Rh*) directly interact with active
(phosphorylated by MEK1) or inactive ERK2 (Fig. 1A,B). Arrest-
ins were pre-incubated with equimolar amount of ERK2, and
then allowed to bind to 1.7-fold molar excess of P-Rh* in native
disc membranes. Rhodopsin-associated proteins were pelleted and
the amount of ERK2 was quantified by Western blot with anti-
ERK antibody. No ERK2 was detected in the pellet in the absence
of rhodopsin-containing membranes or in the presence of P-Rh*
alone, demonstrating that ERK2 does not appreciably bind
rhodopsin. Virtually identical amount of active ERK2 phosphor-
ylated at Thr183 and Tyr185 (PP-ERK2) was pelleted in the
presence of arrestin-2 or arrestin-3 (Fig. 1A,B). Unexpectedly, even
greater amount of PP-ERK2 was brought down in the presence of
arrestin-1. The binding of inactive ERK2 was much lower: it was
only detectable with arrestin-3. These data are the first
demonstration that receptor-associated arrestins 1, 2, and 3
directly bind ERK2. All three subtypes preferentially interact
with the phosphorylated form, and only arrestin-3 forms the
complexes with inactive ERK2 that are stable enough to remain
intact during spin-down of rhodopsin-containing membranes
(Fig. 1A,B).
To test whether free arrestins also bind ERK2, we immobilized
active and inactive ERK2 on CNBr-activated Sepharose,
incubated beads with purified arrestins, washed, and then eluted
bound proteins and quantified them by Western blot with rabbit
polyclonal pan-arrestin antibody (Fig. 1C). In this format arrestin-
1 was not retained by ERK2 columns, suggesting that either free
arrestin-1 does not bind ERK2, or the affinity of this interaction is
too low to maintain the complex throughout the washing
procedure. Both non-visual arrestins bind comparably to active
ERK2 (Fig. 1C). Interestingly, all ‘‘pre-activated’’ mutants of
arrestin-2 and -3 that bind GPCRs more readily than parental
wild type (WT) proteins [32–36] demonstrated reduced PP-ERK2
binding. The presence of 1 mM ATP in the binding assay
significantly reduced the amount of full-length arrestins retained
by the PP-ERK2 columns, with the exception of arrestin-3
(Fig. 1C), suggesting that inside the cell (where ,2 mM ATP is
always present) free arrestin-3 may bind ERK2 with higher affinity
than arrestin-2. Interestingly, the retention of arrestin-2-3A and
arrestin-3-(1–392) was not significantly affected by ATP (Fig. 1C).
These mutants demonstrate greatly enhanced binding to unpho-
sphorylated GPCRs [32,35,36] and even in free state appear to
mimic receptor-bound conformation [37]. As was the case with
receptor-associated arrestins (Fig. 1A,B), free WT arrestins show
weaker binding to inactive ERK2 (Fig. 1C). Arrestin-2 appears to
be significantly more selective: its binding to inactive ERK2 is
,33% of that to active form, whereas for arrestin-3 it is ,67%.
Pre-activated mutants of both arrestins with C-terminal deletions,
arrestin-2-(1–393) and arrestin-3-(1–392), are the least selective in
this regard, comparably binding active and inactive ERK2
(Fig. 1C). Arrestin-3 is the most promiscuous in terms of GPCRs
it binds, the least selective for active phosphorylated forms of the
receptors [21], and appears to be more flexible that arrestin-2 [8].
Truncated mutants are even less selective in receptor binding
[32,33,36,38]. Thus, the degree of preference of different arrestins
for active ERK2 correlates with their selectivity for active
phospho-receptors, suggesting that increased conformational
flexibility underlies the lack of selectivity in both cases.
Next, we tested whether arrestin binding affects ERK2
phosphorylation by MEK1. Purified inactive (unphosphorylated)
ERK2 and purified constitutively active MEK1 (which phosphor-
ylates ERK2) were used to reconstruct this module of c-Raf1-
MEK1-ERK1/2 cascade in vitro (Fig. 2). ERK2 phosphorylation
by MEK1 was evaluated in the absence or presence of purified
arrestins. We found that in the absence of arrestins MEK1
transfers ,2.4 pmol of phosphates. Taking into account that
MEK1 phosphorylates two sites in each ERK2 molecule, this is
Figure 1. ERK2 binding to arrestin-1 and both non-visual
arrestins is direct. A. Active (phosphorylated at T183 and Y185 by
MEK1) or inactive ERK2 (30 pmol) was pre-incubated with or without
30 pmol of indicated arrestin for 20 min at 30uC, then phosphorylated
rhodopsin (50 pmol) was added and incubated in the light (to produce
P-Rh*) in 0.1 ml for 5 min. Rhodopsin-containing membranes were
pelleted through 0.2 M sucrose cushion and dissolved in SDS sample
buffer. ERK2 in the pellet (1/300 of each sample) was quantified by
Western blot using anti-ERK antibodies (Cell Signaling) and known
amounts of purified ERK2 to generate calibration curve. Abbreviations:
Arr1, visual arrestin-1, Arr2, arrestin-2, Arr3, arrestin-3. Representative
blot is shown. B. Quantification of ERK2 binding to P-Rh*-associated
arrestins. C. CNBr-activated Sepharose (30 ml) containing 9 mgo f
covalently attached active phosphorylated (without or with 1 mM
ATP) or inactive ERK2 was incubated with 3 mg of indicated purified
arrestin in 60 ml of binding buffer (50 mM Tris-HCl, pH 7.4, 100 mM KCl,
1 mM EGTA, 1 mM DTT) for 20 min at 30uC. The beads were washed
twice with 1 ml of ice-cold binding buffer supplemented with 0.01 mg/
ml BSA. Bound arrestins were eluted with SDS sample buffer and
quantified by Western blot, where known amounts of respective
arrestins were run alongside samples to generate calibration curves.
Means 6 SD of three independent experiments are shown in panels B
and C.
doi:10.1371/journal.pone.0028723.g001
Arrestin-mediated ERK1/2 activation
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(Fig. 2). In the presence of arrestin-2 or arrestin-3 the extent of
ERK2 phosphorylation was increased by 33 or 41%, respectively.
Thus, free non-visual arrestins moderately facilitate the phosphor-
ylation of ERK2 by MEK1. These data suggest that non-visual
arrestins also bind MEK1.
The effect of arrestin-2 and arrestin-3 binding to the b2-
adrenergic receptor on its interactions with c-Raf1, MEK1,
and ERK2 in cellular environment
The first report on the role of arrestins in the activation of c-
Raf1-MEK1-ERK1/2 cascade suggested that only receptor-
bound arrestins interact with c-Raf1 and ERK1/2, whereas
MEK1 does not bind arrestins directly, but is recruited via c-Raf1
and ERK to the complex [29]. Subsequent studies showed that all
three kinases bind free non-visual arrestins and even separately
expressed N- and C-domains of arrestin-2 and –3 that do not bind
GPCRs, and that ERK demonstrates the lowest affinity of the
three [31]. MEK1 interaction with free arrestin-2 was indepen-
dently confirmed by another group [39]. However, the effects of
arrestin-2 and -3 conformation and receptor binding on their
interaction with these kinases were never systematically investi-
gated. Therefore, we used two known conformationally biased
forms of arrestin-2 and -3, ‘‘pre-activated’’ 3A mutants [32,35,36]
and mutants ‘‘frozen’’ in the basal state by a 7-residue deletion in
the inter-domain hinge (D7) [22,25,26,28] to address this question
in COS-7 cells expressing only endogenous b2AR, or additional
plasmid-encoded b2AR at significantly greater level.
We found that the stimulation of endogenous b2AR by an
agonist isoproterenol dramatically increased ERK2 binding to
arrestin-2 and arrestin-3 (Fig. 3). Over-expression of b2AR
resulted in the formation of an arrestin-receptor complex
independent of isoproterenol stimulation and further increased
the binding of ERK2 to arrestins (Fig. 3). Apparently, at high levels
of b2AR, which is known to have significant constitutive activity
[40], basal arrestin-b2AR association is fairly high and is not
significantly enhanced by isoproterenol stimulation. Pre-activated
3A mutants bind ERK2 much better than corresponding wild type
(WT) arrestins. Since 3A mutation forcibly detaches the arrestin
C-tail [37], similar to receptor binding [10,13,18], which makes
3A mutants mimics of the receptor-bound state, these results are in
agreement with the evidence that ERK2 preferentially binds
receptor-associated arrestins (Fig. 1) [29]. Co-expression of b2AR
with 3A mutants further enhanced arrestin-ERK2 interaction
(Fig. 3). Unexpectedly, we found that D7 mutants of both arrestins
also bind ERK2 significantly better than WT proteins or even 3A
mutants (Fig. 3). This is consistent with reported ability of D7
mutants of arrestin-2 and -3 to recruit ERK1/2 to microtubules,
which they bind with high affinity [22]. In agreement with
impaired ability of D7 mutants to bind GPCRs [22,28], we found
that neither isoproterenol stimulation nor b2AR over-expression
affected ERK2 binding to D7 forms of either arrestin (Fig. 3).
Thus, ERK2 preferentially interacts with arrestins in receptor-
bound and microtubule-associated conformation, whereas free
arrestins in the basal state show the lowest level of association with
this kinase.
In contrast to ERK2 (Fig. 3), MEK1 association with both
arrestins in unstimulated cells was readily detectable (Fig. 4).
Isoproterenol stimulation with or without b2AR over-expression
did not appreciably affect MEK1 binding to WT arrestin-2,
arrestin-3, and their D7 mutants (Fig. 4). Interestingly, MEK1 co-
immunoprecipitated with 3A mutants was dramatically increased
by b2AR over-expression regardless of isoproterenol stimulation
(Fig. 4). Thus, receptor binding does not significantly affect MEK1
interactions with WT arrestins, but enhances MEK1 binding to
conformationally loose [37] 3A mutants. As far as interactions with
ERK2 and MEK1 are concerned, no subtype-specific differences
between arrestin-2 and –3 and their respective mutants were
apparent in the environment of living cells (Figs. 3, 4).
In contrast to ERK2 and MEK1, the binding of c-Raf1 to WT
arrestin-2 and -3 was differentially affected by b2AR over-
expression (Fig. 5). The presence of extra b2AR resulted in a
dramatic increase in c-Raf1 binding to arrestin-2, whereas in case
of arrestin-3 receptor effect was only marginal (Fig. 5). This
difference is in agreement with recent discovery that alanine
substitution of R307 in arrestin-2 greatly reduces c-Raf1 binding
and its ability to facilitate ERK1/2 activation in cells, whereas
homologous K308A mutation in arrestin-3 does not [30]. When
the two subtypes were rendered conformationally flexible by 3A
mutation, b2AR over-expression comparably increased c-Raf1
binding to both non-visual arrestins (Fig. 5). Similar to ERK2 and
MEK1, more c-Raf1 co-immunoprecipitated with D7 mutants
than with WT forms of either arrestin. C-Raf1 binding to
arrestin-2-D7 was moderately increased by b2AR over-expres-
sion, likely reflecting remaining ability of arrestin-2-D7t ob i n d
receptors [22].
To summarize, isoproterenol activation of the endogenous
receptor present at relatively low levels resulted in detectable
increase only of ERK2 interaction with WT arrestins (Fig. 3),
which was previously found to have the lowest propensity to
associate with free arrestins [31]. In contrast, significant over-
expression of b2AR increased the binding of ERK2 and c-Raf1,
but not MEK1, to WT arrestins (Figs. 3, 4, and 5). As could be
expected, in the case of 3A mutants that bind GPCRs more readily
than WT proteins [32,36,38,41], the interaction with all three
kinases is increased by receptor over-expression, whereas D7
mutants impaired in receptor binding ability are essentially
unresponsive to b2AR (Figs. 3, 4, and 5). Unexpectedly, we found
that D7 mutants of arrestin-2 and -3 bind ERK2 and c-Raf1 better
than parental WT arrestins (Figs. 3, 5). The same tendency was
Figure 2. Free non-visual arrestins enhance ERK2 phosphory-
lation by MEK1. A, B. ERK2 (12 pmol) was incubated with MEK1
(2 pmol) in 0.1 ml of 50 mM Hepes-Na, pH 7.2, 100 mM NaCl, and
0.1 mM [c-
32P]ATP in the absence (control) or presence of 4.4 pmol of
arrestin-2 (Arr2), arrestin-3 (Arr3), or arrestin-3-(1–393) (Arr3-(1–393)) for
30 min at 30uC. The reaction was stopped by MeOH-precipitation of the
proteins. The pellet was dissolved in SDS sample buffer and subjected
to SDS-PAGE. The gels were stained, dried, and exposed to X-ray film to
visualize radiolabeled bands (panel A). ERK2 bands were cut out and
32P
incorporation was quantified by scintillation counting (panel B). Means
6 SD of four independent experiments are shown. (**) p,0.01, as
compared to control.
doi:10.1371/journal.pone.0028723.g002
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significance (Fig. 4). Thus, the interactions of non-visual arrestins
with the kinases c-Raf1 and ERK2 are very sensitive to the arrestin
conformation, whereas the binding of MEK1 is minimally affected
by the functional state of arrestins.
Receptor-stimulated arrestin-dependent ERK activation
Next, we tested whether arrestin-ERK2 interaction correlates
with receptor-dependent ERK2 activation. To this end, we
expressed HA-ERK2 with arrestin-2-Flag (Fig. 6A) or arrestin-3-
Flag (Fig. 6D) in COS-7 cells and stimulated endogenous b2AR
Figure 3. Conformational dependence of the interaction of non-visual arrestins with ERK2. COS-7 cells were transfected with WT, 3A, or
D7 mutant forms of Flag-tagged arrestin-2 (A) or arestin-3 (B), along with ERK2-HA, with or without HA-b2AR. Cells were serum starved overnight
24 hours post-transfection and treated for 10 min at 37uC with or without 10 mM b2AR agonist isoproterenol. Cells were lysed, and arrestins were
immunoprecipitated with anti-Flag antibody, and co-immunoprecipitated ERK2 and b2AR were detected with anti-HA antibody. Bar graphs show the
ratio of co-immunoprecipitated ERK2 to immunoprecipitated arrestin. The data from three independent experiments were statistically analyzed by
ANOVA. The significance of the differences is indicated, as follows: * or
&,p ,0.05; ** or
&&,p ,0.01, as compared to corresponding within group basal
level of ERK2 co-immunoprecipitation (black bars);
a or
$ or
#,p ,0.05 compared to WT control (black bar in WT group).
doi:10.1371/journal.pone.0028723.g003
Figure 4. The binding MEK1 is insensitive to arrestin conformation. COS-7 cells were transfected with WT, 3A, or D7 mutant forms of Flag-
tagged arrestin-2 (A) or arrestin-3 (B), along with MEK1-HA, with or without HA-b2AR. Cells were serum starved overnight 24 hours post-transfection
and treated for 10 min at 37uC with or without 10 mM b2AR agonist isoproterenol. Cells were lysed, and arrestins were immunoprecipitated with anti-
Flag antibody, and co-immunoprecipitated MEK1 and b2AR were detected with anti-HA antibody. Bar graphs show the ratio of co-
immunoprecipitated MEK1 to immunoprecipitated arrestin. The data from three independent experiments were analyzed by ANOVA.
&,p ,0.05,
as compared to corresponding within group basal level of MEK1 co-immunoprecipitation (black bars).
doi:10.1371/journal.pone.0028723.g004
Arrestin-mediated ERK1/2 activation
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rine), antagonists (propranolol, alprenolol), or inverse agonists
(ICI118551, carazolol). Unexpectedly, we found that the amount
of ERK2 co-immunoprecipitated with arrestin-2 (Fig. 6B) or
arrestin-3 (Fig. 6E) was significantly increased by agonists,
antagonists, and inverse agonists. Since these ligands were shown
to induce distinct conformational changes in b2AR [42], these
data indicate that arrestins bind more than one conformational
state of the receptor, and this binding promotes similar increases in
ERK2 interaction. Importantly, the level of ERK2 phosphoryla-
tion was also increased by different ligands in cells expressing
arrestin-2 (Fig. 6C) and arrestin-3 (Fig. 6F). Inverse agonists
ICI118551 and carazolol induced the most dramatic increase in
ERK2 association with arrestins and significant increase in ERK2
activation (Fig. 6), supporting the idea that these compounds are in
fact arrestin-biased agonists [43]. Presumed antagonists propran-
olol and alprenolol (that actually have partial agonist activity [40])
also promoted ERK2 binding to arrestins and ERK2 phosphor-
ylation, albeit to a lesser degree (Fig. 6). Agonists isoproterenol and
epinephrine produced disproportionally larger ERK2 activation
relative to its association with arrestins (Fig. 6), likely because, in
contrast to other compounds tested, these ligands increase G
protein activation, and ERK can be also activated by GPCRs via
G-protein mediated pathways [44].
Therefore, to exclude G protein-mediated mechanisms, we
performed the next set of experiments in arrestin-2/3 double
knockout (DKO) MEFs [45], where ERK2 activation by b2AR
inverse agonists is strictly arrestin-dependent. An inverse b2AR
agonist ICI118551, was previously shown to act as an arrestin-
biased agonist [46]. Indeed, we did not detect appreciable ERK1/
2 activation by ICI118551 via endogenous b2AR in DKO MEFs
(Fig. 7). We found that the expression of WT arrestin-2 rescues the
ability of ICI118551 to stimulate ERK1/2 phosphorylation.
Interestingly, arrestin-2-D7 was also effective, in contrast to
arrestin-2-3A mutant (Fig. 7).
To determine which b2AR ligands enhance ERK1/2 phosphor-
ylation in arrestin-dependent fashion, we compared ERK1/2
activation in DKO MEFs expressing GFP (control), WT arrestin-
2, as well as D7 or 3A mutants (Fig. 8A,B). In all cases we detected
robust ERK1/2 activation in response to isoproterenol and
epinephrine, further confirming that this effect is mediated by G
protein, rather than arrestins. In this model the antagonists
propranolol and alprenolol did not affect ERK1/2 phosphorylation
regardless of arrestin expression (Fig. 8). Only cells expressing WT
arrestin-2 and D7 mutantshowedERK1/2 activation inresponseto
ICI118551; however, we did not detect a statistically significant
response to carazolol(Fig. 8A,B), which activatedERK1/2 inCOS-
7 cells over-expressing arrestins (Fig. 6). To determine possible
reasonforthisdifference,wecompared the expression ofarrestinsin
COS7 cells and DKO-MEFs, and found that the latter express all
arrestinsatmuch lowerlevels(Fig.8C).Thus,ICI118551appearsto
be more potent activator of arrestin-mediated signaling, effective
even at fairly low arrestin expression levels.
Discussion
In addition to classical G protein-mediated signaling, GPCRs
were shown to initiate several signaling pathways via bound
arrestins, which lead to the activation of ERK1/2 [29], c-Jun N-
terminal kinase 3 (JNK3) [47], and p38 [48]. The ERK1/2
activating module consists of three kinases: c-Raf1 phosphorylates
MEK1, which in its turn phosphorylates ERK1/2 on both
tyrosine and threonine residues [49] within the activation loop.
ERK1/2 activation by GPCRs can be mediated by the activation
of Ras, PKC, tyrosine kinases (e.g., c-Src), trans-activation of
receptor tyrosine kinases, or via arrestins. ERK1/2 activity
controls many cellular functions, including proliferation, differen-
Figure 5. Conformational dependence of arrestin interactions with c-Raf1. COS-7 cells were transfected with WT, 3A, or D7 mutant forms of
Flag-tagged arrestin-2 (A) or arestin-3 (B), along with c-Raf1-HA, with or without HA-b2AR. Cells were serum starved overnight 24 hours post-
transfection and treated for 10 min at 37uC with or without 10 mM b2AR agonist isoproterenol. Cells were lysed, and arrestins were
immunoprecipitated with anti-Flag antibody, and co-immunoprecipitated c-Raf1 and b2AR were detected with anti-HA antibody. Bar graphs show
the ratio of co-immunoprecipitated c-Raf1 to immunoprecipitated arrestin. The data from three independent experiments were analyzed by ANOVA.
*o r
& or
a,p ,0.05, as compared to corresponding within group basal level of c-Raf1 co-immunoprecipitation (black bars);
$ or
#,p ,0.05, compared
to WT control (black bar in WT group).
doi:10.1371/journal.pone.0028723.g005
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result in different physiological responses than those achieved by G
protein activation. G protein activation of ERK1/2 results in the
translocation of active ERK to the nucleus, where it can
phosphorylate and activate various transcription factors [50]. In
contrast, when ERK1/2 is activated via arrestin-dependent
mechanism, active ERK1/2 largely remains in the cytoplasm,
where it can phosphorylate non-nuclear substrates [51].
Figure 6. The effect of different b2AR ligands on ERK2 binding to arrestins and ERK2 activation. HA-tagged ERK2 was co-expressed with
Flag-tagged WT arrestin-2 (A,B,C), or arrestin-3 (D,E,F) in COS-7 cells. Cells were serum starved 24 hours after transfection and stimulated for 10 min
at 37uC with 10 mM of indicated b2AR ligands. Arrestins were immunoprecipitated with anti-Flag antibody, and co-immunoprecipitated ERK2 was
visualized with anti-HA antibody. The binding of ERK2 to arrestin-2 (B) or arrestin-3 (E) was significantly increased by treatment with ligands. C,D.
ERK1/2 activation in cell lysates was determined by Western blot with anti phospho-ERK1/2 antibody. Means 6 SD of 3–4 independent experiments
are shown in bar graphs; representative blots are shown in panels A and D. ANOVA with Bonferroni post-hoc test revealed the following differences:
*, p,0.05; **, p,0.01; ***, p,0.001, as compared to untreated cells.
doi:10.1371/journal.pone.0028723.g006
Arrestin-mediated ERK1/2 activation
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for the c-Raf1-MEK1-ERK1/2 cascade, their direct interactions
with any of these kinases were never experimentally demonstrated.
Here using purified proteins we have unambiguously shown for
the first time that ERK2 directly binds arrestin-1, -2, and -3
(Fig. 1). The experiments with pure proteins under strictly
controlled conditions revealed that all receptor-bound arrestins
recruit active (phosphorylated by MEK1) ERK2 more efficiently
than inactive ERK2, and that arrestin-1 is the most selective,
whereas arrestin-3 is the least selective in this regard (Fig. 1). These
results are compatible with the model where receptor-associated
arrestin facilitates ERK1/2 phosphorylation and retains generated
active ERK in the complex, which would localize active ERK to
the cytoplasm [29,52], in contrast to ERK activated via other
mechanisms, which translocates to the nucleus. This is the first
plausible mechanistic explanation for cytoplasmic localization of
ERK1/2 activated via arrestin-dependent mechanism. We also
detected measurable interaction of active and inactive ERK2 with
free arrestin-2 and –3, but not with free arrestin-1 (Fig. 1C), which
suggests that non-visual arrestins can come to the receptor ‘‘pre-
loaded’’ with bound ERK, which would facilitate its activation in
response to GPCR stimulation. Using purified proteins we also
demonstrated for the first time that arrestins facilitate ERK2
activation by MEK1 (Fig. 2), a function that was proposed [29,52]
but never proven. The magnitude of this effect in the in vitro assay
was modest, likely due to fairly high concentrations of ERK2,
MEK1, and arrestins used. However, these proof-of-principle
experiments suggest that arrestin impact is likely much greater in
cells, where the ‘‘concentrating’’ effect of binding of the two
kinases would be much stronger due to significantly lower absolute
concentrations of the proteins involved. Our data are compatible
with two distinct roles of arrestin. One possibility is that ERK2
binding to arrestin changes its conformation, making it a better
substrate for MEK1. For example, it was recently shown using
purified proteins that ‘‘scaffold’’ Ste5 in yeast acts by making
MAPK Fus3 (but not related kinase Kss1) a better substrate for
MAPKK Ste7, rather than by bringing Ste7 and Fus3 together
[53]. In the second model arrestin can act as a true scaffold,
bringing both MEK1 and ERK2 into close proximity to each
other, thereby facilitating the phosphorylation of ERK2 by
MEK1. Simple scaffolding mechanism was recently demonstrated
for the arrestin-MKK4-JNK3 signaling module reconstituted from
pure proteins [54]. Detailed kinetic studies of the activity of the
arrestin- MEK1-ERK2 complex reconstructed from pure proteins
are necessary to elucidate the exact mechanism of arrestin action.
Previously we found that ERK2 co-immunoprecipitation from
cells with free arrestins is barely detectable without cross-linking
[55], whereas receptor-associated arrestins readily co-immunopre-
cipitate with ERK2 (Fig. 3). These data suggest that ERK2
binding is highly sensitive to arrestin conformation. To gain
further insight into confromational preference of ERK2, we co-
expressed it with three distinct forms of arrestins: a) WT with
normal conformational flexibility; b) ‘‘pre-activated’’ 3A mutants
with detached C-tail that partially mimic receptor-bound state
[32,36]; c) D7 mutants with the deletion of seven residues in the
inter-domain hinge, which significantly impedes receptor binding
[22,25,28] by ‘‘freezing’’ arrestin in the basal conformation. Our
data show that conformational change induced by arrestin
recruitment to b2AR dramatically increases ERK2 binding to
both non-visual arrestins (Fig. 3). Unexpectedly, we found that
ERK2 also avidly binds D7 mutants, so that free WT arrestins
appear to be its least favorite partners (Fig. 3). ERK2 binding to
both non-visual arrestins shows the same conformational depen-
dence (Fig. 3). MEK1 demonstrates much higher binding to both
arrestins in their basal state and does not show appreciable
conformational dependence in its interactions with arrestin-2 or -3
(Fig. 4). Indeed, in the experiments where we immunoprecipitated
Flag-tagged arrestins and immunoblotted for kinases, all of which
Figure 7. WT and D7 mutant of arrestin-2 rescue b2AR-mediated ERK activation in response to ICI118551 in DKO MEFs. DKO MEFs
were infected with retrovirus encoding GFP (control, -), or untagged WT arrestin-2 (A2-WT), arrestin-2-3A (A2-3A), or arrestin-2-D7 (A2-D7). The cells
were serum-starved 48 hours post-infection for 2 hours, stimulated with 1 mM ICI118551 for 10 min at 37uC, lysed, and analyzed by Western blot.
Means 6 SD of 3–4 independent experiments are shown in bar graphs; representative blots are shown below. *, p,0.05; **, p,0.01.
doi:10.1371/journal.pone.0028723.g007
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considerable amounts of co-immunoprecipitated receptor with
ERK2 (Fig. 3) and c-Raf1 (Fig. 5), but not with MEK1 (Fig. 4),
indicating that a significant fraction of ERK2- and c-Raf1-
associated arrestin is bound to the receptor, whereas most of
MEK1-associated arrestin is free. These data suggest that arrestins
recruited to active phosphorylated receptors are more likely to be
pre-loaded with MEK1 than with ERK. We found that arrestin-2
binding to c-Raf1 is much more sensitive to the receptor interaction
than that of arrestin-3 (Fig. 5). Since distinct structural features of
arrestin-3 also result in lower selectivity for particular functional
forms of the receptor than that of arrestin-2 [8], these data suggest
that higher conformational flexibility of arrestin-3 is responsible for
more promiscuous interactions with GPCRs and other signaling
proteins. Markedly different effects of receptor bindingon arrestin-2
and -3 interaction with c-Raf1 are consistent with distinct ability of
these subtypes to scaffold c-Raf1-MEK1-ERK1/2 cascade [56].
To determine how receptor-dependent changes in arrestin
interactions with these kinases translate into agonist-dependent
ERK1/2 activation, we used b2AR that is endogenously expressed
in most cultured cells at physiologically relevant levels, and took
advantage of the availability of arrestin-biased agonists for this
receptor [43]. Relatively low levels of endogenous arrestins in COS-
7 cells ensure that exogenously expressed arrestin is the predom-
inant species. We found that the expression of WT arrestin-2 or -3,
which are the most sensitive to receptor interaction (Figs. 3, 4, and
5), enhanced the phosphorylation of endogenous ERK1/2 in
response to b2AR stimulation by unbiased agonists adrenaline and
isoproterenol, antagonists alprenolol and propranolol that show low
agonist activity[40], aswell as arrestin-biased agonistscarazololand
ICI118551 (Fig. 6). ERK1/2 phosphorylation induced by carazolol
and ICI118551, which are inverse agonists for G protein activation,
is comparable to that induced by unbiased agonists isoproterenol
and adrenaline that can promote ERK activation via G proteins
andarrestins(Fig.6),suggesting that a significantfractionofERK1/
2 is activated via arrestin-mediated mechanism.
To conclusively dissect arrestin-dependent and arrestin-inde-
pendent mechanisms, we compared WT MEFs, where ERK1/2
can be activated via both pathways, and DKO MEFs lacking non-
visual arrestins [45], where only G protein-mediated pathway is
operative. Indeed, we found that while ERK1/2 phosphorylation
in response to b2AR agonists that promote receptor coupling to G
protein is essentially the same, the response to ICI118551 is
completely lost in DKO MEFs, indicating that it is mediated by
non-visual arrestins absent in these cells (Fig. 7). The advantage of
DKO MEFs is that one can be confident that the expressed form
of arrestin is the only one present. For subsequent experiments we
chose arrestin-2, which showed more pronounced changes in
kinase interactions in response to receptor binding (Figs. 3, 4, and
5). We found that WT arrestin-2 and D7 mutant rescue ERK1/2
response to ICI118551 in DKO MEFs, whereas the 3A mutant
does not (Fig. 7). Next we tested a wider range of b2AR ligands in
DKO MEFs expressing GFP (control), WT arrestin-2, 3A, or D7
mutant (Fig. 8). We found that arrestin expression in DKO MEFs
was 5–6 times lower than in COS-7 cells (Fig. 8C). In these
conditions only ICI118551 induced robust ERK1/2 activation,
indicating that it is more potent stimulator of arrestin-mediated
signaling than carazolol.
To summarize, here we demonstrated for the first time that
arrestins directly binds ERK2, determined the conformations of
arrestin-2 and -3 preferred by c-Raf1 and ERK2, and showed that
MEK1 similarly interacts with arrestins in all conformational
states. We found that ERK2 and c-Raf1 interact with the arrestin-
receptor complex better than with free arrestins. Unexpectedly, we
also found that D7 mutants with significantly reduced ability to
bind receptors readily interact with ERK2 and c-Raf1. Interest-
ingly, WT arrestin-2 and D7 mutant comparably rescue arrestin-
dependent activation of ERK1/2 in response to receptor
stimulation by arrestin-biased ligands. Since dramatically reduced
binding of D7 forms of arrestin-1, -2, and -3 was described using
light-activated phosphorhodopsin [22,28], which appears to bind
G protein and arrestin equally well, our data suggest that arrestin-
2-D7 is less impaired in binding receptors in a distinct
conformation induced by arrestin-biased agonists. Further struc-
tural dissection of receptor conformations that preferentially
engage G proteins and arrestins requires the solution of crystal
structures of receptors in complex with these two types of partners.
So far, only one structure of a GPCR with bound signaling
protein, b2AR-Gs complex, has been solved [57].
Materials and Methods
Materials
[c-
32P]ATP was from Perkin-Elmer. All restriction enzymes
were from New England Biolabs. All other chemicals were from
sources previously described [30,31,58].
Protein purification and in vitro interactions of purified
proteins
Rhodopsin was purified from cow eyes, phosphorylated, and
regenerated by 11-cis-retinal generously supplied by Dr. R. K.
Crouch (Medical University of South Carolina, Charleston, SC),
as described [59]. Bovine arrestins were expressed in E. coli and
purified, as described [58], with slight modifications for individual
subtypes [8,10,14]. Constitutively active MEK1, and inactive
ERK2 were expressed in E. coli and purified, as described [60].
ERK2 was activated in vitro (phosphorylated at T183 and Y185 by
MEK1) as described [60].
ERK2 interactions with the receptor-bound arrestins
Active (phosphorylated at T183 and Y185 by MEK1) or
inactive ERK2 (30 pmol) was preincubated with or without
30 pmol of purified arrestins for 20 min at 30uC, then phosphor-
ylated rhodopsin (50 pmol) was added and incubated in the light
(to produce P-Rh*) for 5 min (final volume 0.1 ml). Rhodopsin-
containing membranes were pelleted through 0.2 M sucrose
cushion, as described [61]. The pellets were dissolved in SDS
sample buffer. ERK2 in the pellet (1/300 of each sample) was
quantified by Western blot using anti-ERK antibodies (Cell
Figure 8. ERK2 activation by different b2AR ligands in DKO MEFs. A. DKO MEFs were infected with retrovirus encoding GFP, untagged WT
arrestin-2 (A2-WT), arrestin-2-3A (A2-3A), or arrestin-2-D7 (A2-D7). Serum-starved cells were stimulated with indicated b2AR ligands, lysed, and
analyzed by Western blot. Representative blots are shown. The expression of different forms of arrestin-2 is compared in the blot below. B. Phospho-
ERK1/2 bands were quantified. Means 6 SD of 3 independent experiments are shown. C. Comparison of arrestin expression levels in COS-7 cells (5 mg
protein/lane) and DKO MEFs (10 mg protein/lane) was performed by Western blot with anti-arrestin antibody. Standards containing indicated
amounts of purified arrestin-2 were run along with cell lysates to generate calibration curve. Arrestin expression was measured by quantitative
Western in COS-7 cells: A2-WT, 100.1 pmol/mg; A2-3A, 81.1 pmol/mg; A2-D7, 92.8 pmol/mg. Arrestin expression in DKO MEFs was much lower: A2-
WT, 13.2 pmol/mg; A2-3A, 12.3 pmol/mg; A2-D7, 21.7 pmol/mg.
doi:10.1371/journal.pone.0028723.g008
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same gel to generate calibration curve.
ERK2 interactions with the free arrestins
CNBr-activated Sepharose beads (30 ml) containing 9 mgo f
covalently attached active phosphorylated (without or with 1 mM
ATP) or inactive ERK2 were incubated with 3 mg of indicated
purified arrestins in 60 ml of binding buffer (50 mM Tris-HCl,
pH 7.4, 100 mM KCl, 1 mM EGTA, 1 mM DTT) for 20 min. at
30uC. The beads were washed twice with 1 ml of ice-cold binding
buffer supplemented with 0.01 mg/ml BSA. Bound arrestins were
eluted with SDS sample buffer and quantified by Western blot
with rabbit polyclonal pan-arrestin antibody, as described [38,62].
Known amounts of respective purified arrestins were run on each
gel to generate calibration curves, as described [63].
ERK2 phosphorylation by purified MEK1
ERK2 (12 pmol) was incubated with MEK1 (2 pmol) in 0.1 ml
of 50 mM Hepes-Na, pH 7.2, 100 mM NaCl, and 0.1 mM
[c-
32P]ATP in the absence (control) or presence of 4.4 pmol of
arrestin-2, arrestin-3, or arrestin-3-(1–393) for 30 min at 30uC.
The reaction was stopped by MeOH-precipitation of the proteins.
The pellet was dissolved in SDS sample buffer and subjected to
SDS-PAGE. The gels were stained, dried, and exposed to X-ray
film to visualize radiolabeled bands. ERK2 bands were cut out and
32P incorporation was quantified by scintillation counting.
Co-immunoprecipitation and Western blotting
Monkey kidney COS-7 cells were transfected with the indicated
plasmids using Lipofectamine
TM 2000 (Invitrogen; Carlsbad, CA),
according to the manufacturers protocol (3 ml of Lipofectamine
TM
2000 per 1 mg of DNA). 24 hours post-transfection, cells were
serum-starved and lysed with lysis buffer (50 mM Tris, 2 mM
EDTA, 250 mM NaCl, 10% glycerol, 0.5% Nonidet P-40, 1 mM
NaVO3, 10 mM N-ethylmaleimide, benzamidine and phenyl-
methylsulfonylfluoride) on ice for 20 min. Cell debris were pelleted
by centrifugation for 10 min at 10,0006 g. Lysates were
precleared with 30 ml of protein G agarose, followed by incubation
with rabbit anti-FLAG antibody for 2 hours and by the addition of
30 ml of protein G agarose beads for 2 hours. The beads were then
washed 3 times with lysis buffer, and bound proteins were eluted
with Laemmli SDS buffer. In experiments involving ERK2, prior
to lysis the cells were treated with 1 mM cross-linking reagent
dithiobis(succinimidyl propionate) (DSP; Pierce) for 30 min
followed by 2 mM Tris-HCl, pH 7.5, for 15 min at room
temperature. The proteins were separated by SDS PAGE (10%)
and transferred to polyvinylidene difluoride membrane (Millipore,
Bedford, MA). Blots were incubated with primary antibodies from
Cell Signaling (mouse anti-HA (6E2) mAb #2367, 1:1500; mouse
anti-p44/42 ERK1/2 (L34F12) mAb #4696, 1:1000; and mouse
anti-p44/42 phospho-ERK1/2 (T202/Y204), (E10) mAb
#9106S, 1:1000), or Sigma (mouse anti-FLAG M2, #F3165,
1:1500; rabbit anti-FLAG #F7425), followed by anti-mouse
horseradish peroxidase-conjugated secondary antibodies from
Jackson ImmunoResearch. Protein bands were visualized by
enhanced chemiluminescence (ECL, Pierce) followed by exposure
to X-ray film. The bands were quantified using VersaDoc with
QuantityOne software (Bio-Rad Laboratories).
Arrestin-dependent ERK activation in cells
COS-7 cells. COS-7 cells were transfected using
Lipofectamine
TM 2000 (Invitrogen; Carlsbad, CA), according to
manufacturer’s protocol (3 ml of Lipofectamine
TM 2000 per 1 mg
of DNA) with Flag-tagged arrestin-2 together with ERK2-HA. 24–
48 hours post-transfection, cells were serum starved for 24
hours and then treated for 10 min at 37uC with saturating
concentrations of isoproterenol (10 mM), epinephrine (10 mM),
propranolol (10 mM), alprenolol (1 mM), ICI118551 (1 mM) or
carazolol (100 nM). COS-7 were then harvested and lysed in
50 mM Tris, 2 mM EDTA, 100 mM NaCl, 1% Nonidet P-40,
supplemented with protease and phosphatase inhibitors cocktails
(Roche 04693124001 and 04906845001, respectively) on ice for
20 min.
Mouse embryonic fibroblasts (MEFs). For retrovirus
production, human embryonic kidney (HEK) 293T cells were
transfected using Lipofectamine
TM 2000 (Invitrogen; Carlsbad,
CA), according to the manufacturer’s protocol (3 mlo f
Lipofectamine
TM 2000 per 1 mg of DNA) with the following
constructs: pVPack-GP (Stratagene, 217566), pVack-VSV-G
(Stratagene, 217567), together with pFB-arrestin-2, pFB-arrestin-
2-3A, pFB-arrestin-2-D7, or pFB-GFP (control). 24–48 hours post-
transfection, media containing the virus produced by HEK293T
cells was collected and used to infect arrestin-2/3 double knockout
MEFs (a generous gift of Dr. R. J. Lefkowitz, Duke University)
[45]. Fresh virus-containing media was used daily for 3 days. Then
MEFs were serum starved for 2 hours and treated with 1 mM
ICI118551, a biased ligand of b2AR, which is an inverse agonist of
G protein signaling and an agonist of arrestin recruitment [43], or
10 mM b2AR agonist isoproterenol for 10 min at 37uC. MEFs
were harvested and lysed in 50 mM Tris, 2 mM EDTA, 100 mM
NaCl, 1% Nonidet P-40, supplemented with protease and
phosphatase inhibitors cocktails (Roche 04693124001 and
04906845001, respectively) on ice for 20 min.
Statistical analysis
The data were analyzed using one-way or two-way ANOVA
(SAS Institute), as appropriate for particular experimental design,
followed by Bonferroni-Dunn post-hoc test with correction for
multiple comparisons.
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